HK1078880A1 - Molecular antigen arrays using a virus like particle derived from the ap205 coat protein - Google Patents
Molecular antigen arrays using a virus like particle derived from the ap205 coat proteinInfo
- Publication number
- HK1078880A1 HK1078880A1 HK05110669.4A HK05110669A HK1078880A1 HK 1078880 A1 HK1078880 A1 HK 1078880A1 HK 05110669 A HK05110669 A HK 05110669A HK 1078880 A1 HK1078880 A1 HK 1078880A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- virus
- antigen
- vlp
- coat protein
- particle derived
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 101710132601 Capsid protein Proteins 0.000 title 1
- 101710094648 Coat protein Proteins 0.000 title 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 title 1
- 101710125418 Major capsid protein Proteins 0.000 title 1
- 101710141454 Nucleoprotein Proteins 0.000 title 1
- 101710083689 Probable capsid protein Proteins 0.000 title 1
- 238000003491 array Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010070863 Toxicity to various agents Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 231100000572 poisoning Toxicity 0.000 abstract 1
- 230000000607 poisoning effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18123—Virus like particles [VLP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Addiction (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39612602P | 2002-07-17 | 2002-07-17 | |
PCT/EP2003/007572 WO2004007538A2 (fr) | 2002-07-17 | 2003-07-14 | Reseaux d'antigenes moleculaires |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1078880A1 true HK1078880A1 (en) | 2006-03-24 |
Family
ID=30115977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05110669.4A HK1078880A1 (en) | 2002-07-17 | 2005-11-24 | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein |
Country Status (15)
Country | Link |
---|---|
US (3) | US7138252B2 (fr) |
EP (2) | EP1532167B1 (fr) |
JP (3) | JP4726483B2 (fr) |
CN (2) | CN102061288A (fr) |
AT (1) | ATE542828T1 (fr) |
AU (1) | AU2003246690B2 (fr) |
BR (1) | BR0312935A (fr) |
CA (1) | CA2489410C (fr) |
HK (1) | HK1078880A1 (fr) |
IL (1) | IL165605A0 (fr) |
MX (1) | MXPA05000277A (fr) |
NZ (1) | NZ538083A (fr) |
RU (2) | RU2324704C2 (fr) |
WO (1) | WO2004007538A2 (fr) |
ZA (1) | ZA200410046B (fr) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2407897A1 (fr) * | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Jeu ordonne d'antigenes moleculaires |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
JP4598519B2 (ja) * | 2002-06-20 | 2010-12-15 | サイトス バイオテクノロジー アーゲー | アジュバントとして使用するためのパッケージ化されたウィルス様粒子:調製法及び使用法 |
BR0312935A (pt) * | 2002-07-17 | 2005-06-21 | Cytos Biotechnology Ag | Partìcula semelhante a vìrus, muteìna, vetores para produzir a referida partìcula e proteìna recombinante, composição, processo para produção de fileira ordena e repetitva de antìgeno, molécula de ácido nucléico, célula hospedeira, método para produção da referida partìcula e uso da composição de vacina |
EP1523334A2 (fr) * | 2002-07-18 | 2005-04-20 | Cytos Biotechnology AG | Conjugues haptene-porteur et utilisations de ceux-ci |
CN101711865A (zh) * | 2002-07-19 | 2010-05-26 | 希托斯生物技术股份公司 | 含有淀粉样β1-6抗原阵列的疫苗组合物 |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
US20090028886A1 (en) * | 2004-08-04 | 2009-01-29 | Cytos Biotechnology Ag | Carrier conjugates of gnrh-peptides |
EP1791870A1 (fr) * | 2004-09-21 | 2007-06-06 | Cytos Biotechnology AG | Particules ressemblant à un virus comprenant une protéine de fusion de la protéine de coque de ap205 et d'un polypeptide antigénique |
KR20070059207A (ko) * | 2004-10-05 | 2007-06-11 | 사이토스 바이오테크놀로지 아게 | Vlp-항원 컨쥬게이트 및 백신으로서 그의 용도 |
BRPI0516775A (pt) | 2004-10-25 | 2008-09-23 | Cytos Biotechnology Ag | ensaios de polipeptìdeo de antìgeno de inibidor gástrico (gip) e seus usos |
US20090123471A1 (en) * | 2004-10-29 | 2009-05-14 | Cytos Biotechnology Ag | T-Cadherin antigen arrays and uses thereof |
GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
JP2008523132A (ja) * | 2004-12-13 | 2008-07-03 | サイトス バイオテクノロジー アーゲー | Il−15抗原アレイとその使用法 |
KR20070112225A (ko) * | 2005-03-18 | 2007-11-22 | 사이토스 바이오테크놀로지 아게 | 고양이 알레르겐 컨쥬게이트 및 그의 용도 |
EP1746165A1 (fr) | 2005-07-21 | 2007-01-24 | Cytos Biotechnology AG | Procédé de fermentation échelonnable |
NZ563708A (en) | 2005-05-26 | 2010-08-27 | Cytos Biotechnology Ag | Scalable fermentation process |
WO2006134125A1 (fr) * | 2005-06-14 | 2006-12-21 | Cytos Biotechnology Ag | Conjugues d'antigenes et leurs utilisations |
EP1736538A1 (fr) * | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Procédé pour la purification préparative de particules pseudo-virales (VLPs) |
ES2310062B1 (es) | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
CN101267834B (zh) | 2005-09-28 | 2013-06-05 | 赛托斯生物技术公司 | 白介素-1偶联物及其用途 |
US20070166735A1 (en) * | 2005-12-08 | 2007-07-19 | South Dakota State University | Methods of in vitro propagation and detection of infectious prion |
RU2451523C2 (ru) | 2005-12-14 | 2012-05-27 | Цитос Биотехнологи Аг | Упакованные иммуностимулирующей нуклеиновой кислотой частицы, предназначенные для лечения гиперчувствительности |
US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
ES2427994T3 (es) | 2006-06-12 | 2013-11-05 | Cytos Biotechnology Ag | Procesos para empaquetar oligonucleótidos en partículas de tipo viral de bacteriófagos de ARN |
EP2066347A1 (fr) * | 2006-09-28 | 2009-06-10 | Cytos Biotechnology AG | Mutéines de l'interleukine-1 liées à des particules de type viral destinées au traitement de maladies associées à l'il-1 |
WO2008100609A1 (fr) * | 2007-02-16 | 2008-08-21 | The Salk Institute For Biological Studies | Nouvelle antitoxine et plateforme vaccinale à base de vlp de nodavirus |
JPWO2008133141A1 (ja) * | 2007-04-24 | 2010-07-22 | 東洋紡績株式会社 | オスモチン組換えタンパク質およびその製造方法、並びにその利用 |
EP2190473B1 (fr) | 2007-08-15 | 2013-01-16 | Circassia Limited | Peptide à formation réduite de dimères |
US8222206B2 (en) * | 2008-03-04 | 2012-07-17 | Taiwan Advance Bio-Pharm Inc. | Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H |
CA2721657A1 (fr) * | 2008-04-22 | 2009-10-29 | Cytos Biotechnology Ag | Compositions de vaccin pour le traitement de la dengue et leurs utilisations |
MX2011006077A (es) | 2008-12-09 | 2011-09-01 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige. |
WO2010122164A1 (fr) | 2009-04-23 | 2010-10-28 | Cytos Biotechnology Ag | Pseudo-particules virales du bactériophage φcb5 |
EP2424570A1 (fr) * | 2009-04-30 | 2012-03-07 | Cytos Biotechnology AG | Compositions d'hémagglutinine de virus grippal et leurs utilisations |
NZ598356A (en) | 2009-07-30 | 2014-06-27 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
TR201808222T4 (tr) * | 2009-09-03 | 2018-07-23 | Pfizer Vaccines Llc | PCSK9 aşısı. |
WO2011097266A1 (fr) | 2010-02-02 | 2011-08-11 | Amano Enzyme Usa, Ltd. | Utilisation de protéases pour intolérance au gluten |
EP2942061A3 (fr) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Vaccin peptidique ige ch3 |
WO2012131504A1 (fr) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Vaccin à base de pcsk9 |
MX2014001142A (es) | 2011-07-29 | 2014-02-27 | Selecta Biosciences Inc | Nanoportadores sinteticos que generan respuestas inmunitarias humorales y de linfocitos t citotoxicos (ctl). |
SG11201403445YA (en) | 2011-12-22 | 2014-07-30 | Hoffmann La Roche | Full length antibody display system for eukaryotic cells and its use |
JP6362543B2 (ja) | 2012-02-23 | 2018-07-25 | ジュノ セラピューティクス ゲーエムベーハー | 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離 |
US20210320597A1 (en) * | 2012-05-11 | 2021-10-14 | The Regents Of The University Of California | Virus-Based Piezoelectric Energy Generation |
DE102013105144A1 (de) * | 2013-05-17 | 2014-11-20 | Arno Thaller | Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment |
US10195257B2 (en) | 2013-07-28 | 2019-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response |
EP3104877B1 (fr) | 2014-02-11 | 2020-01-22 | The USA, as represented by The Secretary, Department of Health and Human Services | Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
CA3010975A1 (fr) | 2015-01-15 | 2016-07-21 | University Of Copenhagen | Pseudo-particule virale a presentation efficace des epitopes |
MX2018002926A (es) * | 2015-09-08 | 2019-01-30 | Univ Zuerich | Composiciones contra alergia a los gatos. |
EP3141600A1 (fr) | 2015-09-11 | 2017-03-15 | Institut National de la Recherche Agronomique | Polypeptides de fusion de la proteine d'enveloppe de nepovirus et leurs utilisations |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
JP7195141B2 (ja) * | 2015-10-22 | 2022-12-23 | ジュノ セラピューティクス ゲーエムベーハー | 形質導入のための方法、キット、作用物質および装置 |
WO2017071713A1 (fr) | 2015-10-30 | 2017-05-04 | University Of Copenhagen | Pseudo-particule virale à présentation efficace des épitopes |
CN118146389A (zh) | 2016-09-02 | 2024-06-07 | 美国卫生与公众服务部 | 稳定化的第2组流感血凝素茎区三聚体及其用途 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
AR111625A1 (es) | 2017-04-27 | 2019-07-31 | Juno Therapeutics Gmbh | Reactivos de partículas oligoméricas y métodos de uso de los mismos |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
MX2020010410A (es) | 2018-04-09 | 2021-01-15 | Checkmate Pharmaceuticals | Empaquetado de oligonucleotidos en particulas similares a virus. |
WO2020163719A2 (fr) * | 2019-02-08 | 2020-08-13 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Vaccins contre le virus de la grippe à base de nanoparticules et leurs utilisations |
EP3955918A1 (fr) | 2019-04-17 | 2022-02-23 | COMPASS Pathfinder Limited | Procédés pour traiter les troubles neurocognitifs, la douleur chronique, et pour réduire l'inflammation |
EP4048795A1 (fr) | 2019-10-23 | 2022-08-31 | Checkmate Pharmaceuticals, Inc. | Agonistes de récepteur du type rig-i synthétiques |
US20230063876A1 (en) * | 2020-03-02 | 2023-03-02 | Unm Rainforest Innovations | Virus-Like Particle Vaccines for Opioid Drugs |
EP4141110A1 (fr) | 2020-04-24 | 2023-03-01 | Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" | Procédé de production de particules de bactériophages de la famille levivirus |
EP4153564A4 (fr) | 2020-05-19 | 2024-06-19 | Cybin IRL Limited | Dérivés de tryptamine deutérés et procédés d'utilisation |
CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
CN114634578B (zh) * | 2020-12-15 | 2024-04-02 | 榕森生物科技(北京)有限公司 | 针对新型冠状病毒感染的疫苗组合物 |
CN114632148B (zh) * | 2020-12-15 | 2024-08-09 | 榕森生物科技(北京)有限公司 | 病原样抗原疫苗及其制备方法 |
CN112480245B (zh) * | 2020-12-19 | 2023-08-18 | 上海佰君生物科技有限公司 | 一种疏水性环状肽配基纯化人免疫球蛋白g的应用 |
BR112023020640A2 (pt) | 2021-04-12 | 2023-12-05 | Saiba AG | Partículas similares a vírus de bacteriófago ap205 modificadas |
WO2022229817A1 (fr) | 2021-04-28 | 2022-11-03 | Bavarian Nordic A/S | Vaccins comprenant des particules pseudo-virales présentant des antigènes du sars-cov-2 et leurs méthodes d'utilisation |
WO2024068265A2 (fr) | 2022-09-30 | 2024-04-04 | Bavarian Nordic A/S | Particules de type virus présentant des antigènes du sars-cov-2 utilisées en tant que vaccins de rappel et leurs utilisations |
CN116987700B (zh) * | 2023-07-13 | 2024-02-20 | 杭州赛基生物科技有限公司 | 一种人白细胞介素-5重组蛋白及其制备方法 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5334A (en) * | 1847-10-16 | Improvement in cutter-heads for plan ing-machines | ||
US394A (en) * | 1837-09-21 | Mode of regulating the temperature of inkiwg-rollers and ink used | ||
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
CA1319101C (fr) | 1986-09-03 | 1993-06-15 | Marta Iris Sabara | Proteine de capside nucleique de rotavirus avec ou sans peptides liants comme porteurs de macromolecules immunologiques |
BR8707471A (pt) | 1986-09-22 | 1988-09-13 | Univ Emory | Vacina e processo de preparacao |
US5143726A (en) | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4918166A (en) | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
GB8903313D0 (en) | 1989-02-14 | 1989-04-05 | Wellcome Found | Conjugates |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
DE69018926T2 (de) | 1989-09-04 | 1995-08-24 | Wellcome Found | Vakzine gegen Bordetella. |
WO1991010741A1 (fr) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation d'anticorps xenogeniques |
US5178882A (en) | 1990-06-22 | 1993-01-12 | The Regents Of The University Of California | Viral decoy vaccine |
US5334394A (en) | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
EP0563091A1 (fr) | 1990-12-20 | 1993-10-06 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | VACCINS A BASE DE l'ANTIGENE D'ENVELOPPE DU VIRUS DE L'HEPATITE B |
GB9114003D0 (en) | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
ATE180407T1 (de) | 1993-01-11 | 1999-06-15 | Dana Farber Cancer Inst Inc | Induktion der antworten zytotoxischer t- lymphozyten |
AU6172194A (en) | 1993-02-08 | 1994-08-29 | Paravax, Inc. | Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
AT402898B (de) | 1994-08-08 | 1997-09-25 | Int Centre Genetic Eng & Bio | Molekulares präsentiersystem |
EP0817854A2 (fr) | 1995-03-31 | 1998-01-14 | Wolf, Hans, Prof. Dr. | Systeme de presentation d'antigenes fonde sur des particules similaires a des retrovirus |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
IL125590A (en) | 1996-03-01 | 2001-08-26 | Novartis Ag | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies |
US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
AU745951B2 (en) | 1997-08-05 | 2002-04-11 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | New immunoprotective influenza antigen and its use in vaccination |
US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
US6054312A (en) | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
EP1054689B1 (fr) | 1998-02-12 | 2003-09-10 | Immune Complex, Corporation | Proteines noyaux de l'hepatite b strategiquement modifiees et leurs derives |
US5990085A (en) | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
TWI227241B (en) | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
ES2258869T3 (es) | 1998-10-21 | 2006-09-01 | The United States Government As Represented By The Department Of Health And Human Services | Particulas similares a virus para la induccion de autoanticuerpos. |
US6380364B1 (en) | 1998-11-23 | 2002-04-30 | Loyola University Of Chicago | Chimeric biotin-binding papillomavirus protein |
WO2000032227A2 (fr) * | 1998-11-30 | 2000-06-08 | Cytos Biotechnology Ag | Presentation moleculaire ordonnee d'antigenes, procede de preparation et utilisation |
IL143475A0 (en) | 1998-12-04 | 2002-04-21 | Biogen Inc | Hepatitis b virus core antigen particles and vaccines and pharmaceutical compositions containing the same |
PL350992A1 (en) | 1999-02-25 | 2003-02-24 | Smithkline Beecham Biolog | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses |
CA2365970A1 (fr) | 1999-04-07 | 2000-10-12 | Thomas Jefferson University | Peptides synthetiques issus de chimiokines |
WO2001062284A2 (fr) | 2000-02-21 | 2001-08-30 | Pharmexa A/S | Nouvelle methode de regulation negative d'amyloide |
CA2407897A1 (fr) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Jeu ordonne d'antigenes moleculaires |
US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7128911B2 (en) * | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
ES2294173T3 (es) | 2001-09-21 | 2008-04-01 | Coloplast A/S | Dispositivo para la administracion de un agente activo a la piel humana. |
US7115266B2 (en) * | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
KR20050044314A (ko) * | 2001-11-07 | 2005-05-12 | 사이토스 바이오테크놀로지 아게 | 뼈 질환 치료용 항원 어레이 |
JP3787697B2 (ja) | 2002-01-08 | 2006-06-21 | 独立行政法人理化学研究所 | 重イオンビーム照射によるキメラ植物の作出方法 |
BR0312935A (pt) * | 2002-07-17 | 2005-06-21 | Cytos Biotechnology Ag | Partìcula semelhante a vìrus, muteìna, vetores para produzir a referida partìcula e proteìna recombinante, composição, processo para produção de fileira ordena e repetitva de antìgeno, molécula de ácido nucléico, célula hospedeira, método para produção da referida partìcula e uso da composição de vacina |
EP1523334A2 (fr) * | 2002-07-18 | 2005-04-20 | Cytos Biotechnology AG | Conjugues haptene-porteur et utilisations de ceux-ci |
CN101711865A (zh) * | 2002-07-19 | 2010-05-26 | 希托斯生物技术股份公司 | 含有淀粉样β1-6抗原阵列的疫苗组合物 |
US7537767B2 (en) * | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
KR20050115913A (ko) * | 2003-03-26 | 2005-12-08 | 사이토스 바이오테크놀로지 아게 | Melan―a 펩티드 유사체-바이러스-양-입자컨쥬게이트 |
SI1656332T1 (sl) | 2003-07-25 | 2017-08-31 | Waste 2 Green, Llc | Metoda in sistem za obdelavo odpadnih snovi od živali, ki vsebujejo sečnino |
BRPI0516775A (pt) * | 2004-10-25 | 2008-09-23 | Cytos Biotechnology Ag | ensaios de polipeptìdeo de antìgeno de inibidor gástrico (gip) e seus usos |
KR20070112225A (ko) * | 2005-03-18 | 2007-11-22 | 사이토스 바이오테크놀로지 아게 | 고양이 알레르겐 컨쥬게이트 및 그의 용도 |
-
2003
- 2003-07-14 BR BR0312935-7A patent/BR0312935A/pt not_active IP Right Cessation
- 2003-07-14 RU RU2005104235/13A patent/RU2324704C2/ru not_active IP Right Cessation
- 2003-07-14 AT AT03763829T patent/ATE542828T1/de active
- 2003-07-14 EP EP03763829A patent/EP1532167B1/fr not_active Expired - Lifetime
- 2003-07-14 AU AU2003246690A patent/AU2003246690B2/en not_active Ceased
- 2003-07-14 EP EP10011277A patent/EP2351770A1/fr not_active Withdrawn
- 2003-07-14 NZ NZ538083A patent/NZ538083A/en not_active IP Right Cessation
- 2003-07-14 WO PCT/EP2003/007572 patent/WO2004007538A2/fr active Application Filing
- 2003-07-14 CA CA2489410A patent/CA2489410C/fr not_active Expired - Fee Related
- 2003-07-14 MX MXPA05000277A patent/MXPA05000277A/es active IP Right Grant
- 2003-07-14 JP JP2004520607A patent/JP4726483B2/ja not_active Expired - Fee Related
- 2003-07-14 CN CN2010101587965A patent/CN102061288A/zh active Pending
- 2003-07-14 US US10/617,876 patent/US7138252B2/en not_active Expired - Fee Related
- 2003-07-14 CN CN038168626A patent/CN1668637B/zh not_active Expired - Fee Related
-
2004
- 2004-12-07 IL IL16560504A patent/IL165605A0/xx unknown
- 2004-12-13 ZA ZA200410046A patent/ZA200410046B/en unknown
-
2005
- 2005-11-24 HK HK05110669.4A patent/HK1078880A1/xx not_active IP Right Cessation
-
2006
- 2006-11-20 US US11/601,687 patent/US7494656B2/en not_active Expired - Fee Related
-
2007
- 2007-12-03 RU RU2007144895/13A patent/RU2007144895A/ru not_active Application Discontinuation
-
2008
- 2008-12-22 US US12/341,763 patent/US20100092508A1/en not_active Abandoned
-
2009
- 2009-11-25 JP JP2009267660A patent/JP2010075196A/ja active Pending
-
2010
- 2010-11-05 JP JP2010248015A patent/JP2011087580A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2003246690B2 (en) | 2010-03-11 |
CN1668637A (zh) | 2005-09-14 |
CN1668637B (zh) | 2010-05-26 |
JP2010075196A (ja) | 2010-04-08 |
US20100092508A1 (en) | 2010-04-15 |
RU2324704C2 (ru) | 2008-05-20 |
US20040076611A1 (en) | 2004-04-22 |
RU2007144895A (ru) | 2009-06-10 |
JP4726483B2 (ja) | 2011-07-20 |
IL165605A0 (en) | 2006-01-15 |
JP2006510347A (ja) | 2006-03-30 |
US20070128219A1 (en) | 2007-06-07 |
EP2351770A1 (fr) | 2011-08-03 |
BR0312935A (pt) | 2005-06-21 |
US7138252B2 (en) | 2006-11-21 |
AU2003246690A1 (en) | 2004-02-02 |
US7494656B2 (en) | 2009-02-24 |
ATE542828T1 (de) | 2012-02-15 |
NZ538083A (en) | 2006-08-31 |
WO2004007538A3 (fr) | 2004-03-04 |
ZA200410046B (en) | 2006-03-29 |
CN102061288A (zh) | 2011-05-18 |
JP2011087580A (ja) | 2011-05-06 |
MXPA05000277A (es) | 2005-03-31 |
CA2489410A1 (fr) | 2004-01-22 |
WO2004007538A2 (fr) | 2004-01-22 |
RU2005104235A (ru) | 2005-09-10 |
EP1532167B1 (fr) | 2012-01-25 |
CA2489410C (fr) | 2015-01-13 |
EP1532167A2 (fr) | 2005-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1078880A1 (en) | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein | |
MX2007003171A (es) | Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico. | |
WO2002056905A3 (fr) | Jeu ordonne d'echantillons d'antigenes moleculaires | |
HK1077009A1 (en) | Vaccine compositions containing amyloid beta1-6 antigen arrays | |
WO2006097530A3 (fr) | Conjugues d'allergene du chat et utilisations associees | |
IL165003A0 (en) | Ghrelin-carrier conjugates | |
HK1068355A1 (en) | Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases | |
WO2006045796A3 (fr) | Systemes d'antigenes de polypeptides inhibiteurs gastriques et utilisations | |
WO2005117983A3 (fr) | Conjugues entraineurs des peptides du tnf | |
WO2006063974A3 (fr) | Jeux ordonnes d'antigenes il-15 et leurs utilisations | |
WO2005068639A3 (fr) | Conjugues a base de ghreline et d'un vehicule | |
WO2006027300A3 (fr) | Conjugues vecteurs des peptides de gonadoliberine (gnrh) | |
WO2003039225A3 (fr) | Ensemble ordonne d'antigenes destines au traitement de maladies osseuses | |
WO2003059386A3 (fr) | Conjuges-vecteurs de proteines prion | |
WO2007008093A3 (fr) | Procede permettant de fabriquer un vaccin recombine contre la maladie hemorragique virale du lapin, vaccin et application d'un antigene recombine dans la fabrication du vaccin | |
MXPA04003901A (es) | Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas. | |
MXPA04003900A (es) | Disposiciones de antigenos para el tratamiento de enfermedades oseas. | |
WO2001030989A3 (fr) | Procede de creation de populations divergentes de molecules et de proteines d'acide nucleique | |
WO2003074003A3 (fr) | Immunogenes destines au traitement de maladies malignes et infectieuses | |
JP2005512987A5 (fr) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20150714 |